Gut Imaging for Function & Transit in Cystic Fibrosis Study 2

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 3, 2019

Primary Completion Date

October 29, 2020

Study Completion Date

October 29, 2020

Conditions
Cystic Fibrosis
Interventions
DRUG

Tezacaftor/Ivacaftor + Ivacaftor

As per description in arms.

DRUG

Placebo oral tablet

As per description in arms

Trial Locations (1)

NG7 2UH

Nottingham University Hospitals NHS Trust, Nottingham

All Listed Sponsors
collaborator

Vertex Pharmaceuticals Incorporated

INDUSTRY

collaborator

Cystic Fibrosis Foundation

OTHER

collaborator

Cystic Fibrosis Trust

OTHER

collaborator

University of Nottingham

OTHER

collaborator

Nottingham University Hospitals Charity

UNKNOWN

lead

Nottingham University Hospitals NHS Trust

OTHER

NCT04006873 - Gut Imaging for Function & Transit in Cystic Fibrosis Study 2 | Biotech Hunter | Biotech Hunter